Despite progress in corporate cybersecurity, life sciences operational technology is still vulnerable to increasingly sophisticated threats
The Life sciences industry has entered a time of incredible innovation- with drugs that significantly prolong lives, treatments that cure diseases, and customized medications and medical devices that meet consumers’ health and lifestyle needs.
These advances depend upon equally ground breaking connected technologies that enable accelerated, cost-effective, and customized production. Continuing to innovate on all these fronts is critical to a thriving and productive industry. This will require bringing OT and IT cybersecurity to parity and staying several steps ahead of threat actors whose actions could bring innovation to a halt. Life sciences organizations have made significant progress when it comes to protecting IT networks and critical data in the corporate environment. The same attention must now be paid to the OT environment. The future of life sciences innovation depends on it.
Given the intense focus on cybersecurity programs to protect IT, why has there been so little emphasis on securing OT environments? The answer is that cybersecurity budgets have traditionally excluded funds for OT, as addressing the risks correctly and at a scale was viewed as prohibitively expensive.
By contrast today’s organizations are making the argument to corporate boards, committees and other decision makers that it is critical to invest in OT cybersecurity measures due to the seriousness of the risks if this environment is exposed. Specifically they are driving awareness of how certain market, operational, and regulatory factors are contributing to wider risk landscape.
If you would like to learn more about this landscape and minimizing associated risks and how KPMG can help you and your business please click below to access the full paper.